期刊文献+

新型CpG ODN增强乙肝疫苗诱导IgG2a类抗体产生的实验研究 被引量:4

Study of New CpG ODNs on enhancement of IgG2a production induced by hepatitis B vaccine
在线阅读 下载PDF
导出
摘要 目的寻找能增强乙肝疫苗刺激IgG2a类抗体产生,使机体处于Th1样免疫环境的新型乙肝疫苗佐剂。方法选用自行设计的A、B、C型CpGODN,并以发表的A、B型CpGODN作为阳性对照,与重组乙肝疫苗混合后于第0、4周免疫BALB/c小鼠,用ELISA法检测免疫小鼠血清中HBsAb水平及种类。结果各型CpGODN都能增强乙肝疫苗刺激HBsAb的产生水平,CpGODN+乙肝疫苗免疫的小鼠血清中HBsAb类型为IgG2a>>IgG1,而单独应用商品化重组乙型肝炎疫苗的小鼠血清中HBsAb类型为IgG1>>IgG2a。结论各型CpGODN对重组乙型肝炎疫苗[含Al(OH)3佐剂]均具有增效作用,而且可以诱导机体产生倾向于Th1途径的免疫应答反应。 Objective:To search for new adjuvant for hepatitis B vaccine that could stimulate the production of IgG2a and induce Th1-like immune circumstance. Methods.BALB/c mice were immunized with recombinant hepatitis B vaccine only or combined with CpG ODNs designed by our lab( including type A, B and C) and CpG ODNs published in articles at 0th and 4th week. The HBsAb level and the IgG subsets in the serum of mice were measured by ELISA. Results:All types of CpG ODN could enhance the production of HBsAb stimulated by hepatitis B vaccine. The level of IgG subsets of mice immunized with hepatitis B vaecine combined with CpG ODN was IgG2a 〉 〉 IgG1 , and that of mice immunized with hepatitis B vaccine only was IgG1〉〉IgG2a. Conclusion:All types of CpG ODN can enhance the effect of recombinant hepatitis B vaccine and induce Th1-like immune response.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2006年第11期987-990,996,共5页 Chinese Journal of Immunology
基金 国家自然科学基金海外杰出青年基金资助(30328010)
关键词 CPG ODN 乙型肝炎疫苗 佐剂 IGG2A CpG ODN Hepatitis B vaccine Adjuvant IgG2a
作者简介 丛中一(1978年-),女,博士 指导教师及通讯作者:王丽颖(1958年-),女,教授,博士生导师,主要从事抗肿瘤抗病毒核酸和基因工程重组蛋白抗肿瘤抗病毒方面的研究,E—mail:wlying@mail.jlu.edu.cn。 指导教师及通讯作者:于水利(1955年-),男,教授,博士生导师,主要从事基因工程疫苗方面研究,E-mail:ylyu@mail.jlu.edu.cn
  • 相关文献

参考文献16

  • 1Krieg A M,Yi A K,Matson S et al.CpG motifs in bacterial DNA trigger direct B-cell activation[J].Nature,1995;374(6522):546-549.
  • 2Vollmer J,Weeratna R,Payette P et al.Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities[J].Eur J Immunol,2004;34(1):251-262.
  • 3Hartmann G,Weeratna R D,Ballas Z K et al.Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo[J].J Immunol,2000;164(3):1617-1624.
  • 4Verthelyi D,Kenney R T,Seder R A et al.CpG oligodeoxynucleotides as vaccine adjuvants in primates[J].J Immunol,2002;168(4):1659-1663.
  • 5Nichani A K,Kaushik R S,Mena A et al.CpG oligodeoxynucleotide induction of antiviral effector molecules in sheep[J].Cell Immunol,2004; 227(1):24-37.
  • 6Chu R S,Targoni O S,Krieg A M et al.CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1(Th1) immunity[J].J Exp Med,1997;186(10):1623-1631.
  • 7Finkelman F D,Holmes J,Katona I M et al.Lymphokine control of in vivo immunoglobulin isotype selection[J].Annu Rev Immunol,1990;8:303-333.
  • 8拉米夫定临床应用专家组,万谟彬.2004年拉米夫定临床应用专家共识[J].中华传染病杂志,2004,22(4):283-287. 被引量:89
  • 9刘崇柏,苏崇鳌.乙型肝炎疫苗免疫及存在的问题[J].中国计划免疫,2004,10(3):159-162. 被引量:63
  • 10Davis H L,Weeranta R,Waldschmidt T J et al.CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen[J].J Immunol,1998;160(2):870-876.

二级参考文献12

  • 1Lok AS,McMahon BJ.Chronic hepatitis B[].Hepatology.2001
  • 2Maria Buti,Rafael Esteban.Entecavir, FTC, L-RMAU, LdT and others[].Journal of Hepatology.2003
  • 3Fontana RJ.Mangement of patients with decompensated HBV cirrhosis[].Seminars in Liver Disease.2003
  • 4Hom X,Little NR,Gardner SD,et al.Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection[].Pediatric Infectious Disease.2004
  • 5Kobayashi S,Ide T,Sata M,et al.Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers[].Journal of Hepatology.2001
  • 6Li LL,Chun TW,Yin ML,et al.Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy[].Hepatology.2000
  • 7Liaw YF,Sung JJY,Chow WC,et al.Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial[].Hepatology.2003
  • 8Liaw YF,Leung N,Guan R,et al.Asian-pacific consensus statement on the management of chronic hepatitis B:[].An updateJ Gastroenterol Hepatol.2003
  • 9Jonas MM,Kelley DA,Mizerski J,et al.Clinic trial of lamivudine in children with chronic hepatitis B[].The New England Journal of Medicine.2002
  • 10Sokal EM.Drug treatment of pediatric chronic hepatitis B[].Paediatric Drugs.2002

共引文献150

同被引文献31

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部